[
  {
    "ts": null,
    "headline": "INCY Stock Down on Disappointing Skin Disease Study Data",
    "summary": "Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.",
    "url": "https://finnhub.io/api/news?id=adaac6207f3df8824b561a597da594bd91760d590fa95b0f1f7048f32378ba6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742324400,
      "headline": "INCY Stock Down on Disappointing Skin Disease Study Data",
      "id": 133327550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.",
      "url": "https://finnhub.io/api/news?id=adaac6207f3df8824b561a597da594bd91760d590fa95b0f1f7048f32378ba6c"
    }
  },
  {
    "ts": null,
    "headline": "Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib",
    "summary": "Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click here to read why INCY is a Buy.",
    "url": "https://finnhub.io/api/news?id=dedaea0a9c83f0527a7985352d76f4055267123038af2645f8760bfd0031f318",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742312397,
      "headline": "Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib",
      "id": 133235092,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199321843/image_2199321843.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click here to read why INCY is a Buy.",
      "url": "https://finnhub.io/api/news?id=dedaea0a9c83f0527a7985352d76f4055267123038af2645f8760bfd0031f318"
    }
  },
  {
    "ts": null,
    "headline": "Stoke CEO exits; Medicare drug price talks advance",
    "summary": "Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.",
    "url": "https://finnhub.io/api/news?id=03c6e063f8b9ee00754132703c0de5a55b1975d30a0aafa33d0fd8eeebb1077d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742299500,
      "headline": "Stoke CEO exits; Medicare drug price talks advance",
      "id": 133327551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.",
      "url": "https://finnhub.io/api/news?id=03c6e063f8b9ee00754132703c0de5a55b1975d30a0aafa33d0fd8eeebb1077d"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires",
    "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
    "url": "https://finnhub.io/api/news?id=fd84cf477cc88977d6507af5dd8a01e8f8d89151b625591e59b0781a1283cf0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742290377,
      "headline": "Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires",
      "id": 133327552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]",
      "url": "https://finnhub.io/api/news?id=fd84cf477cc88977d6507af5dd8a01e8f8d89151b625591e59b0781a1283cf0f"
    }
  }
]